Clinical Trial Update: Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating FP-014 (11.25 mg) in advanced prostate cancer has been withdrawn, though the update discusses its efficacy, safety, and pharmacokinet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• FP-014

Snippet

Sponsor: Foresee Pharmaceuticals Co., Ltd. | Conditions: Prostate Cancer | Phase 3 | Status: WITHDRAWN